The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010Development of In-vivo Models of Prion-like Transfer of Alpha-synuclein
Promising Outcomes of Original Grant:
We aimed at assessing the prion-like hypothesis of alpha-synuclein spread. Prions are small proteins that can move between cells, acting as infectious agents... -
MJFF Research Grant, 2010In-vivo SPECT Imaging of Synuclein Aggregation with Morphology Specific Antibody Based Ligands
Promising Outcomes of Original Grant:
The protein alpha-synuclein (a-syn) has been strongly correlated with PD, and small a-syn aggregates are very toxic and may be an early indicator of the disease... -
Therapeutics Development Initiative, 2010Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease
Promising Outcomes of Original Grant:
We are investigating a regulatory enzyme (type-7 cyclic nucleotide phosphodiesterase, PDE7) as a novel therapeutic target for the treatment of Parkinson’s disease... -
Rapid Response Innovation Awards, 2010Biofeedback-based Motor Learning to Ameliorate Freezing of Gait
Objective/Rationale:
Our objective is to demonstrate that an intervention program based on motor learning principles can be applied to train subjects with Parkinson's disease (PD) who suffer from... -
MJFF Research Grant, 2010Patient-specific iPS cell-derived Neurons and Disease-associated LRRK2 Mutations for Parkinson's Disease Research
Objective/Rationale:
Several underlying genetic risk factors are now established for Parkinson’s disease (PD). Mutations in LRRK2 are the most common genetic cause of the selective neurodegeneration... -
Therapeutics Development Initiative, 2010Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease
Objective/Rationale:
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.